SCHEMBL7182792

SCHEMBL7182792

CC(C)(C)Oc1ccc(PC(=O)c2c(C(F)(F)F)cccc2C(F)(F)F)c(OC(C)(C)C)c1.[LiH]

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 1/20 0.33
MAPK10 P53779 1/20 0.33
LMNA P02545 2/20 0.33
MRGPRX4 Q96LA9 2/20 0.33
POLB P06746 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
SCN8A Q9UQD0 1/20 0.32
SCN10A Q9Y5Y9 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
GAA P10253 2/20 0.31
MAPT P10636 1/20 0.31
ATM Q13315 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
SLC22A12 Q96S37 1/20 0.31
PPARG P37231 1/20 0.31
PPARD Q03181 1/20 0.31
PPARA Q07869 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL7182804 0.98 MAPK8 (0.33) MAPK8MAPK10LMNAMRGPRX4POLB
SCHEMBL7180662 0.88 MAPK8 (0.33) MAPK8MAPK10LMNAPOLBMAOA
SCHEMBL7730586 0.85 MAPK8 (0.32) MAPK8MAPK10LMNAMRGPRX4POLB
SCHEMBL7182105 0.85 POLB (0.35) LMNAPOLBMEN1KMT2AMAPT
SCHEMBL7188989 0.84 KIF11 (0.31) LMNAPOLBMAOB
SCHEMBL7186843 0.83 MAPT (0.40) MEN1KMT2AGAAMAPTATM
SCHEMBL7180569 0.83 MAPT (0.44) LMNAMRGPRX4MAOBMEN1KMT2A
Lithium SCHEMBL7182112 0.83 POLB (0.35) LMNAPOLBMEN1KMT2AMAPT
Lithium SCHEMBL7188999 0.81 KIF11 (0.31) LMNAPOLBMAOB
SCHEMBL7187567 0.81 MAPK8 (0.35) MAPK8MAPK10LMNAPOLBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPK8 1733/4885MAPK10 792/4885LMNA 3241/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPK8 2081/4885MAPK10 1079/4885LMNA 3247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.